Show simple item record

dc.contributor.authorHarrison, Palmer D
dc.contributor.authorRoss, PJ
dc.contributor.authorSilcocks, P
dc.contributor.authorGreenhalf, W
dc.contributor.authorFaluyi, O
dc.contributor.authorMa, YT
dc.contributor.authorWadsley, J
dc.contributor.authorRawcliffe, C
dc.contributor.authorNeoptolemos, J
dc.contributor.authorValle, Juan W
dc.contributor.authorWasan, H
dc.contributor.authorStarling, N
dc.contributor.authorPatel, K
dc.contributor.authorBridgewater, J
dc.date.accessioned2019-04-29T09:48:52Z
dc.date.available2019-04-29T09:48:52Z
dc.date.issued2018en
dc.identifier.citationHarrison Palmer D, Ross PJ, Silcocks P, Greenhalf W, Faluyi O, Ma YT, et al. 788TiP ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma. Annals of Oncology. 2018;29(suppl_8).en
dc.identifier.pmidNo PMIDen
dc.identifier.doi10.1093/annonc/mdy282.171en
dc.identifier.urihttp://hdl.handle.net/10541/621726
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy282.171en
dc.titleACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentLiverpool Cancer Trials Unit, University of Liverpool, Liverpool, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T10:25:02Z


Files in this item

Thumbnail
Name:
AO561578.pdf
Size:
104.8Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record